Trial Profile
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Avacincaptad pegol (Primary)
- Indications Stargardt disease
- Focus Therapeutic Use
- Acronyms STAR
- Sponsors IVERIC bio
- 03 Oct 2023 Planned End Date changed from 1 Sep 2024 to 1 Apr 2025.
- 03 Oct 2023 Planned primary completion date changed from 1 Sep 2024 to 1 Apr 2025.
- 03 Oct 2023 Status changed from recruiting to active, no longer recruiting.